Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Carcinoma, Medullary 9Lung Neoplasms 8Thyroid Neoplasms 7Neoplasms 5Neoplasm Metastasis 5Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Ovarian Neoplasms 3Carcinoma, Renal Cell 3Breast Neoplasms 3Stomach Neoplasms 2Pleural Effusion 2Kidney Neoplasms 2Gliosarcoma 2Glioblastoma 2Familial medullary thyroid carcinoma 2Fallopian Tube Neoplasms 2Urinary Bladder Neoplasms 1Thyroid cancer, medullary 1Thyroid Diseases 1Thyroid Cancer, Papillary 1Small Cell Lung Carcinoma 1Recurrence 1Rectal Neoplasms 1Precancerous Conditions 1Peritoneal Neoplasms 1Oligodendroglioma 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1

Interventions

vandetanib 1pertuzumab 1gallium Ga 68 dotatate 1fluorodopa F 18 1Lansoprazole 1Erlotinib Hydrochloride 1(18F)GTP1 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Multiple Endocrine Neoplasia × vandetanib × Clear all
NCT00514046 2020-12-22

Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
17 enrolled 25 charts
Endocrine

Multiple Endocrine Neoplasia, Carcinoma, Medullary, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

Data powered by HemOnc (CC BY 4.0) Colophon âš¡